{'fraction_non_alphanumeric': 0.01911764705882353, 'fraction_numerical': 0.011764705882352941, 'mean_word_length': 5.611650485436893, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Benign intracranial hypertension in a patient treated with ustekinumab for psoriasis

Ustekinumab is a monoclonal antibody, which binds the p40 subunit of IL‐12 and IL‐23 so they are unable to bind to their receptors, ultimately reducing T‐cell‐mediated inflammation in psoriasis. Studies and cases have focused on the risk of infection and malignancy associated with the use of biologics medications; however, there have been limited data available on the potential neurological adverse effects of biologics. We report the case of a 44‐year‐old female with a longstanding history of psoriasis who developed benign intracranial hypertension while on ustekinumab for her psoriasis.